📗 Cite This Artifact
Cross-Disease Therapeutic Targets in 4R-Tauopathies
Cross-Disease Therapeutic Targets in 4R-Tauopathies
Overview
<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Cross-Disease Therapeutic Targets in 4R-Tauopathies</th>
</tr>
<tr>
<td class="label">Disease</td>
<td>Abbreviation</td>
</tr>
<tr>
<td class="label">Progressive Supranuclear Palsy</td>
<td>PSP</td>
</tr>
<tr>
<td class="label">Corticobasal Degeneration</td>
<td>CBD</td>
</tr>
<tr>
<td class="label">Argyrophilic Grain Disease</td>
<td>AGD</td>
</tr>
<tr>
<td class="label">Globular Glial Tauopathy</td>
<td>GGT</td>
</tr>
<tr>
<td class="label">FTDP-17</td>
<td>FTDP-17</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Methylthioninium chloride (MTC)</td>
<td>Tau aggregation inhibitor</td>
</tr>
<tr>
<td class="label">Lithium</td>
<td>GSK-3β inhibitor, reduces tau phosphorylation</td>
</tr>
<tr>
<td class="label">Davunetide (AL-108)</td>
<td>Tau phosphorylation inhibitor</td>
</tr>
<tr>
<td class="label">Sodium phenylbutyrate</td>
<td>Tau acetylation modulator</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Approach</td>
</tr>
<tr>
<td class="label">CSF1R</td>
<td>Pexidartinib, BLZ945 for microglia depletion</td>
</tr>
<tr>
<td class="label">TREM2</td>
<td>Anti-TREM2 antibodies</td>
</tr>
<tr>
<td class="label">CD22</td>
<td>Antibody blockade</td>
</tr>
<tr>
<td class="label">Agent</td>
Cross-Disease Therapeutic Targets in 4R-Tauopathies
Overview
<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Cross-Disease Therapeutic Targets in 4R-Tauopathies</th>
</tr>
<tr>
<td class="label">Disease</td>
<td>Abbreviation</td>
</tr>
<tr>
<td class="label">Progressive Supranuclear Palsy</td>
<td>PSP</td>
</tr>
<tr>
<td class="label">Corticobasal Degeneration</td>
<td>CBD</td>
</tr>
<tr>
<td class="label">Argyrophilic Grain Disease</td>
<td>AGD</td>
</tr>
<tr>
<td class="label">Globular Glial Tauopathy</td>
<td>GGT</td>
</tr>
<tr>
<td class="label">FTDP-17</td>
<td>FTDP-17</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Methylthioninium chloride (MTC)</td>
<td>Tau aggregation inhibitor</td>
</tr>
<tr>
<td class="label">Lithium</td>
<td>GSK-3β inhibitor, reduces tau phosphorylation</td>
</tr>
<tr>
<td class="label">Davunetide (AL-108)</td>
<td>Tau phosphorylation inhibitor</td>
</tr>
<tr>
<td class="label">Sodium phenylbutyrate</td>
<td>Tau acetylation modulator</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Approach</td>
</tr>
<tr>
<td class="label">CSF1R</td>
<td>Pexidartinib, BLZ945 for microglia depletion</td>
</tr>
<tr>
<td class="label">TREM2</td>
<td>Anti-TREM2 antibodies</td>
</tr>
<tr>
<td class="label">CD22</td>
<td>Antibody blockade</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Rapamycin</td>
<td>mTOR inhibition</td>
</tr>
<tr>
<td class="label">Trehalose</td>
<td>TFEB activation, mTOR-independent autophagy</td>
</tr>
<tr>
<td class="label">Curcumin</td>
<td>Autophagy induction</td>
</tr>
<tr>
<td class="label">Urolithin A</td>
<td>Mitophagy enhancement</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Approach</td>
</tr>
<tr>
<td class="label">Tau aggregation</td>
<td>Methylthioninium</td>
</tr>
<tr>
<td class="label">Tau-Specific immunotherapy</td>
<td>Semorinemab</td>
</tr>
<tr>
<td class="label">Tau kinase inhibition</td>
<td>Tideglusib, lithium</td>
</tr>
<tr>
<td class="label">Neuroprotection</td>
<td>CoQ10, IGF-1</td>
</tr>
<tr>
<td class="label">Oculomotor function</td>
<td>3,4-Diaminopyridine</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Approach</td>
</tr>
<tr>
<td class="label">Tau immunotherapy</td>
<td>Semorinemab</td>
</tr>
<tr>
<td class="label">Antibody-based</td>
<td>Anti-tau oligomer</td>
</tr>
<tr>
<td class="label">TREM2 modulation</td>
<td>Anti-TREM2 antibodies</td>
</tr>
<tr>
<td class="label">Synaptic protection</td>
<td>Levetiracetam</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Approach</td>
</tr>
<tr>
<td class="label">Tau acetylation</td>
<td>Salsalate, tributyrin</td>
</tr>
<tr>
<td class="label">Anti-tau antibodies</td>
<td>Various</td>
</tr>
<tr>
<td class="label">Combination therapy</td>
<td>Tau + neuroinflammation</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Rationale</td>
</tr>
<tr>
<td class="label">Oligodendrocyte protection</td>
<td>GOIs are hallmark</td>
</tr>
<tr>
<td class="label">Tau immunotherapy</td>
<td>Pathological tau in glia</td>
</tr>
<tr>
<td class="label">Myelin repair</td>
<td>White matter involvement</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Approach</td>
</tr>
<tr>
<td class="label">Gene silencing</td>
<td>ASOs targeting MAPT</td>
</tr>
<tr>
<td class="label">Haplotype modification</td>
<td>H1c risk haplotype</td>
</tr>
<tr>
<td class="label">Tau reduction</td>
<td>Antisense oligonucleotides</td>
</tr>
<tr>
<td class="label">Disease</td>
<td>Active Trials</td>
</tr>
<tr>
<td class="label">PSP</td>
<td>8</td>
</tr>
<tr>
<td class="label">CBD</td>
<td>3</td>
</tr>
<tr>
<td class="label">AGD</td>
<td>0</td>
</tr>
<tr>
<td class="label">GGT</td>
<td>0</td>
</tr>
<tr>
<td class="label">FTDP-17</td>
<td>0</td>
</tr>
<tr>
<td class="label">Total</td>
<td>11</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Company</td>
</tr>
<tr>
<td class="label">Bepranemab</td>
<td>UCB</td>
</tr>
<tr>
<td class="label">E2814</td>
<td>Eisai</td>
</tr>
<tr>
<td class="label">JNJ-63733657</td>
<td>Janssen</td>
</tr>
<tr>
<td class="label">Tilavonemab</td>
<td>AbbVie</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Target</td>
</tr>
<tr>
<td class="label">LMTM (Methylthioninium)</td>
<td>Tau aggregation</td>
</tr>
<tr>
<td class="label">ASN90</td>
<td>O-GlcNAcase</td>
</tr>
<tr>
<td class="label">Rapamycin</td>
<td>mTOR</td>
</tr>
<tr>
<td class="label">Coenzyme Q10</td>
<td>Mitochondrial function</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Target</td>
</tr>
<tr>
<td class="label">ASO-MAPT</td>
<td>MAPT mRNA</td>
</tr>
<tr>
<td class="label">AAV-tau</td>
<td>Tau reduction</td>
</tr>
<tr>
<td class="label">CRISPR-based</td>
<td>MAPT gene</td>
</tr>
</table>
The 4R-tauopathies represent a group of neurodegenerative disorders characterized by the preferential accumulation of four-repeat (4R) tau isoforms. While [Progressive Supranuclear Palsy (PSP](/diseases/progressive-supranuclear-palsy), [Corticobasal Degeneration (CBD](/diseases/corticobasal-degeneration), [Argyrophilic Grain Disease (AGD](/diseases/argyrophilic-grain-disease), [Globular Glial Tauopathy (GGT](/diseases/globular-glial-tauopathy), and [FTDP-17](/diseases/ftdp-17) share common pathological features centred on tau dysfunction, each disease presents unique therapeutic opportunities and challenges. This page provides a comprehensive comparison of therapeutic targets across these conditions, highlighting both shared pathways and disease-specific approaches.
Diseases Covered
Cross-Disease Mechanisms
Shared Therapeutic Targets
Several therapeutic strategies target common mechanisms across all 4R-tauopathies. These represent the highest-priority opportunities for disease-modifying therapies.
1. Tau-Directed Therapies
Tau protein dysfunction is the central pathological feature across all 4R-tauopathies. The following tau-targeted approaches are under active investigation:
Tau Aggregation Inhibitors
Tau Immunotherapy
Active and passive immunization approaches target pathological tau species:
- AADvac1 (Axon Neuroimmunology): Active vaccine targeting pathological tau; completed Phase I for AD, planned for 4R-tauopathies[@axon]
- Semorinemab (Genentech): Anti-tau monoclonal antibody; failed in PSP, ongoing for CBD
- Lu AF87908 (Lundbeck): Anti-tau antibody targeting 4R-tau; Phase I ongoing
Tau Kinase Inhibitors
The overactivation of tau kinases (GSK-3β, CDK5, JNK) promotes pathological phosphorylation. GSK-3β inhibitors have been explored extensively:
- Lithium: Failed in PSP clinical trials due to tolerability issues
- Valproic acid: Failed in PSP trials
- Tideglusib: Non-selective GSK-3β inhibitor; failed in AD trials
2. Neuroinflammation Modulation
Chronic neuroinflammation drives progression across all 4R-tauopathies. Key targets include:
Microglial Modulation
NLRP3 Inflammasome Inhibition
- MCC950: Potent NLRP3 inhibitor; preclinical promise in AD/PD, under exploration for PSP/CBD
- Dapansutrile: Phase II in inflammatory conditions
Complement Inhibition
- Eculizumab: C5 inhibitor; explored in ALS/FTD
- Anti-C1q antibodies: Preclinical in tauopathy models
3. Autophagy and Proteostasis Enhancement
Tau clearance through autophagy-lysosome and ubiquitin-proteasome pathways is impaired across 4R-tauopathies:
Autophagy Inducers
4. Neuroprotective Agents
Several neuroprotective strategies show promise across multiple 4R-tauopathies:
Mitochondrial Protection
- Coenzyme Q10: Variable results in PSP; ongoing investigations
- Idebenone: Failed in Friedrich's ataxia, under exploration in PSP
- Mitochondrial peptides (MMP): Phase II in PD
Synaptic Protection
- Levetiracetam: Shows cognitive benefits in AD; potential for CBS/PSP
- Ampa Receivers: Ampalon, perampanel: Under investigation
Disease-Specific Therapeutic Targets
Progressive Supranuclear Palsy (PSP)
PSP has the most robust therapeutic development pipeline among 4R-tauopathies:
Key ongoing trials:
- NCT06065016: Tau PET imaging with [18F]-PI-2620 in PSP
- NCT05903290: Coral calcium supplementation in PSP
Corticobasal Degeneration (CBD)
CBD therapeutic development lags behind PSP, though several approaches are emerging:
Argyrophilic Grain Disease (AGD)
AGD lacks disease-specific clinical trials due to diagnostic challenges during life:
Globular Glial Tauopathy (GGT)
GGT is the rarest 4R-tauopathy with no disease-specific clinical trials. Therapeutic approaches are based on shared mechanisms:
FTDP-17
FTDP-17 represents a genetic 4R-tauopathy with unique therapeutic considerations:
Clinical Trial Landscape Summary
Therapeutic Priority Ranking
Based on evidence strength and biological rationale, the following ranking applies across 4R-tauopathies:
Cross-Linking to Related Pages
- [Tau Protein](/proteins/tau)
- [4R-Tau Protein](/proteins/4r-tau)
- [Tauopathy Mechanisms](/mechanisms/tauopathy)
- [PSP Pathway](/mechanisms/psp-pathway)
- [CBD Pathway](/mechanisms/cbd-pathway)
- [Neuroinflammation in 4R-Tauopathies](/mechanisms/neuroinflammation-4r-tauopathies)
- [CBS/PSP Treatment Rankings](/therapeutics/cbs-psp-treatment-rankings)
- [CBS/PSP Daily Action Plan](/therapeutics/cbs-psp-daily-action-plan)
- [Coenzyme Q10 for Neurodegeneration](/therapeutics/coq10-neurodegeneration)
See Also
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
External Links
- [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
- [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)
References
2025-2026 Clinical Trial Updates
Recently Completed and Active Trials
Recent clinical trial data has provided important insights into therapeutic development for 4R-tauopathies:
Tau Immunotherapy Updates
Small Molecule Updates
Gene Therapy and ASO Approaches
Biomarker Development (2025-2026)
Recent advances in biomarker development are improving clinical trial design:
- Plasma p-tau217: now validated for detecting AD pathology in CBS cohorts; higher specificity than p-tau181
- Neurofilament light chain (NfL): established as disease progression marker in both CBS and PSP
- Tau PET ligands: 18F-PI-2620 shows specificity for 4R-tauopathies vs AD
- CSF biomarker panels: Combined NfL + p-tau181 + Aβ42 achieves ~82% accuracy for CBS vs PSP differentiation
Emerging Therapeutic Targets
Several novel approaches have entered the pipeline:
Related Hypotheses
From the [SciDEX Exchange](/exchange) — scored by multi-agent debate
- [Bacterial Enzyme-Mediated Dopamine Precursor Synthesis](/hypothesis/h-7bb47d7a) — <span style="color:#ffd54f;font-weight:600">0.44</span> · Target: TH, AADC
- [SASP-Mediated Complement Cascade Amplification](/hypothesis/h-58e4635a) — <span style="color:#81c784;font-weight:600">0.73</span> · Target: C1Q/C3
- [Targeting Bacterial Curli Fibrils to Prevent α-Synuclein Cross-Seeding](/hypothesis/h-8b7727c1) — <span style="color:#81c784;font-weight:600">0.64</span> · Target: CSGA
- [TREM2-mediated microglial tau clearance enhancement](/hypothesis/h-b234254c) — <span style="color:#ffd54f;font-weight:600">0.55</span> · Target: TREM2
- [Prohibitin-2 Mitochondrial Cross-Seeding Hub Disruption](/hypothesis/h-8bd89d90) — <span style="color:#ffd54f;font-weight:600">0.50</span> · Target: PHB2
- [Microbial Inflammasome Priming Prevention](/hypothesis/h-e7e1f943) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: NLRP3, CASP1, IL1B, PYCARD
- [TREM2 Conformational Stabilizers for Synaptic Discrimination](/hypothesis/h-044ee057) — <span style="color:#ffd54f;font-weight:600">0.58</span> · Target: TREM2
- [TFEB-PGC1α Mitochondrial-Lysosomal Decoupling](/hypothesis/h-e5a1c16b) — <span style="color:#ffd54f;font-weight:600">0.52</span> · Target: TFEB
Related Analyses:
- [TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) 🔄
- [Senolytic therapy for age-related neurodegeneration](/analysis/SDA-2026-04-01-gap-013) 🔄
- [What are the mechanisms by which gut microbiome dysbiosis influences Parkinson's disease pathogenesi](/analysis/SDA-2026-04-01-gap-20260401-225155) 🔄
- [RNA binding protein dysregulation across ALS FTD and AD](/analysis/SDA-2026-04-01-gap-v2-68d9c9c1) 🔄
- [Synaptic pruning by microglia in early AD](/analysis/SDA-2026-04-01-gap-v2-691b42f1) 🔄
▸Metadataorigin_type: v1_polymorphic_backfill
| slug | therapeutics-4r-tauopathy-targets |
| kg_node_id | None |
| entity_type | therapeutic |
| origin_type | v1_polymorphic_backfill |
| source_table | wiki_pages |
| wiki_page_id | wp-5ef9ae91b427 |
| __merged_from | {'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-4r-tauopathy-targets'} |
| _schema_version | 1 |
No provenance edges found
Use ?embed=1 to load the artifact without SciDEX chrome — suitable for iframing into wiki pages or external sites.
<iframe src="http://scidex.ai/artifact/wiki-therapeutics-4r-tauopathy-targets?embed=1" width="100%" height="600" style="border:0;border-radius:8px"></iframe>
[Cross-Disease Therapeutic Targets in 4R-Tauopathies](http://scidex.ai/artifact/wiki-therapeutics-4r-tauopathy-targets)
http://scidex.ai/artifact/wiki-therapeutics-4r-tauopathy-targets